Dynamic activation of lytic cell death-related programs identifies CD14 as a candidate hub gene associated with secondary injury after spinal cord injury - Report - MDSpire

Dynamic activation of lytic cell death-related programs identifies CD14 as a candidate hub gene associated with secondary injury after spinal cord injury

  • By

  • Shenglong Wang

  • Ruoxiang Mei

  • Wenting Xu

  • Xiaochen Su

  • Menghao Teng

  • Xiaoxiao Lou

  • Chen Zhang

  • Shenghua Guo

  • Yingang Zhang

  • July 6, 2026

  • 0 min

Share

Identification of CD14 as a Potential Hub Gene Linked to Secondary Injury

Overview

This study identifies CD14 as a candidate hub gene associated with lytic cell death programs following spinal cord injury (SCI). The findings indicate that lytic cell death-related transcriptional activities are dynamically activated after SCI and are linked to immune-inflammatory responses.

Background

Secondary spinal cord injury (SCI) is characterized by persistent inflammation and oxidative stress, leading to further neuronal damage. Understanding the mechanisms underlying secondary injury is crucial for developing effective therapeutic strategies. This study focuses on the role of lytic cell death in the progression of secondary injury and identifies potential regulatory genes.

Data Highlights

Pyroptosis, necroptosis, and ferroptosis-related transcriptional activities were assessed, revealing significant increases post-SCI.

Key Findings

  • Increased transcriptional activities related to pyroptosis, necroptosis, and ferroptosis were observed after SCI.
  • CD14 was identified as the most robust candidate hub gene linked to lytic cell death indices.
  • Lytic cell death-associated genes were primarily involved in inflammatory responses and immune regulation.
  • External validation in human SCI cohorts supported the upregulation of CD14.
  • Further studies are needed to determine the direct role of CD14 in lytic cell death pathways.

Clinical Implications

The identification of CD14 as a hub gene may provide insights into the inflammatory processes following SCI.

Conclusion

The study highlights the dynamic activation of lytic cell death programs in SCI and positions CD14 as a significant candidate for further investigation.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- The immune dysregulation landscape and dynamic regulation of competing endogenous RNAs in spinal cord injury
  2. Frontiers in Immunology, 2026 -- Microglia-vascular interactions after spinal cord injury: regulatory mechanisms and therapeutic advances
  3. Frontiers in Immunology, 2026 -- Single-cell extracellular vesicle-program scoring maps immunometabolic rewiring and immune crosstalk of mesenchymal stromal cells in intervertebral disc degeneration, prioritizing AP2S1 and CSTB
  4. AO Spine/Praxis Clinical Practice Guidelines for the Management of Acute Spinal Cord Injury: An Introduction to a Focus Issue, 2024
  5. Clinical Practice Guideline: The Diagnosis and Treatment of Acute Spinal Cord Injury - PMC
  6. Frontiers in Immunology — Sex differences in peripheral and local immune responses following spinal cord injury
  7. Effect of blood pressure threshold on adverse outcomes in patients with acute spinal cord injury: a systematic review and meta-analysis | Critical Care | Springer Nature Link
  8. Safety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS): A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Trial
  9. AO Spine/Praxis Clinical Practice Guidelines for the Management of Acute Spinal Cord Injury: An Introduction to a Focus Issue - Brian K. Kwon, Lindsay A. Tetreault, Nathan Evaniew, Andrea C. Skelly, Michael G. Fehlings, 2024
  10. Clinical Practice Guideline: The Diagnosis and Treatment of Acute Spinal Cord Injury - PMC
  11. 16. The sodium-glutamate antagonist riluzole enhances recovery after acute spinal cord injury: reanalysis of the RISCIS randomized controlled trial using a global statistical analytic technique - ScienceDirect
  12. Safety and Efficacy of Riluzole in Traumatic Spinal Cord Injury: A Systematic Review With Meta-Analyses - Luke J. Weisbrod, Thomas T. Nilles-Melchert, Judith R. Bergjord, Daniel L. Surdell, 2024
  13. Pharmacotherapy in the acute phase of secondary spinal cord injury: an updated narrative review | European Journal of Medical Research | Springer Nature Link
  14. Frontiers | Microglia and programmed cell death in spinal cord injury: beyond apoptosis
  15. A Comprehensive Proteomic and Bioinformatic Analysis of Human Spinal Cord Injury Plasma Identifies Proteins Associated with the Complement Cascade and Liver Function as Potential Prognostic Indicators of Neurological Outcome - PubMed

Original Source(s)

Related Content